From: oncodaily.com A phase 1 clinical trial presented at the 2025 Society of Neuro-Oncology Annual Meeting reported encouraging early safety findings for intraventricular HER2-directed CAR T-cell therapy in patients with HER2-positive breast cancer who developed recurrent brain metastases or leptomeningeal metastases (LM)—two of the most devastating complications in advanced HER2-driven disease. Led by Jana Portnow, MD, from City of Hope, …
HER2-Positive Breast Cancer Diet
From: healthline.com Foods such as sugar, saturated fats, and alcohol may promote the spread of HER2-positive breast cancer and should be avoided if you have this cancer. Some other foods may slow the cancer’s progress. Can diet help HER2-positive breast cancer? Your daily diet can affect your overall health. About 18% of all cancersTrusted Source may be related to diet, …
T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer
By: Roman Fabbricatore From: .cancernetwork.com The FDA has granted fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) breakthrough therapy designation as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, according to a news release from the drug’s developer, Daiichi-Sankyo.1 Based on results from the phase 3 DESTINY-Breast09 trial (NCT04784715), the agency’s decision follows data presented during a late-breaking oral …
FDA Grants Breakthrough Therapy Designation to Frontline T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer
By: Chris Ryan From: onclive.com he FDA has granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab for the first-line treatment of adult patients with HER2-positive unresectable or metastatic breast cancer. The designation was supported by data from the phase 3 DESTINY-Breast09 trial (NCT04784715). “This breakthrough therapy designation provides further recognition of the potential benefit of …
HER2 Breast Cancer: The Basics About This Specific Subtype
By: Shalmali Pal From: medpagetoday.com Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 (BRCA1/BRCA2opens in a new tab or window), and lifestyle factors is crucial for risk assessment. In general, the key types of breast canceropens in a new tab …
Novel ADC IBI354 Drives Responses in Pretreated HER2+ Advanced Breast Cancer
By: Chris Ryan From:.onclive.com Key Takeaways IBI354 showed a 59.1% overall response rate and 90.9% disease control rate in HER2-positive breast cancer patients. In the 9 mg/kg subgroup, the overall response rate was 72.4%, with a disease control rate of 89.7%. Treatment-emergent adverse effects occurred in 97.6% of patients, with 39.1% experiencing grade 3 or higher events. IBI354’s mechanism includes …
Researchers identified new indicators for HER2+ breast cancer response to therapy
By: Ana María Rodríguez, Ph.D. From: bcm.edu Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible treatment. Their decision is informed by a comprehensive molecular profile of the patient’s cancer samples that predicts the most likely response of the cancer to treatment. If the profile predicts a high likelihood of …
Which First-line Tx Combo Is Best for HER2+ Breast Cancer?
By: Richard Mark Kirkner From: medscape.com The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for disease progression or death by more than the current standard-of-care treatment. Sara Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, presented this finding and other …
AI Assistance May Boost Accuracy of HER2-Low Scoring for Breast Cancers
By: Wayne Kuznar, Contributing Writer From: medpagetoday.com Artificial intelligence (AI) assistance appeared to enhance pathologists’ accuracy in identifying HER2-low or -ultralow expression in breast cancer tissue, a global study showed, which could cut down on missed opportunities for effective HER2-targeted therapy. Institution of AI as part of a training program to assist pathologists in HER2 scoring of breast cancer samples …
Study Links PAK5 to Poor Outcomes and Drug Resistance in HER2-Positive Breast Cancer
By: Alexandra Gerlach, Associate Editor From: pharmacytimes.com Key Takeaways PAK5 is linked to resistance in HER2-positive breast cancer, correlating with advanced cancer stages and poor outcomes. High PAK5 levels stabilize MALAT1, preventing N-HER2 breakdown and enhancing resistance through a feedback loop. Targeting PAK5 may improve treatment efficacy for patients with limited options after standard therapies fail. Researchers have identified p21-activated …